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appropriate use criteria (AUC) for implantable cardioverter-deﬁbrillators and cardiac resynchronization therapy.
These criteria were developed to critically review clinical situations that may warrant implantation of an implantable
cardioverter-deﬁbrillator or cardiac resynchronization therapy device, and were based on a synthesis of practice
guidelines and practical experience from a diverse group of clinicians. When the AUC was drafted, the writing
committee recognized that some of the scenarios that were deemed “appropriate” or “may be appropriate” were
discordant with the clinical requirements of many payers, including the Medicare National Coverage Determination
(NCD). To charge Medicare for a procedure that is not covered by the NCD may be construed as fraud. Discordance
between the guidelines, the AUC, and the NCD places clinicians in the difﬁcult dilemma of trying to do the “right
thing” for their patients, while recognizing that the “right thing” may not be covered by the payer or insurer. This
commentary addresses these issues. Options for reconciling this disconnect are discussed, and recommendations to
help clinicians provide the best care for their patients are offered. (J Am Coll Cardiol 2014;63:12–4) ª 2014 by
the American College of Cardiology FoundationSince antiquity, the primary responsibility of the physician
has been to serve the best interests of his or her patients. This
responsibility is not negotiable and should never change.
When we take the Hippocratic Oath, we commit ourselves
to doing the “right” thing for our patients. However, “right”
is a relative term, and who deﬁnes or should deﬁne “right” is
not always clear.
In recent years, professional medical associations, including
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our patients (1). Committees of well-respected leaders rigo-
rously review the available data and synthesize guidelines to
improve the effectiveness of care and optimize outcomes.
When there is a paucity of data, recommendations may
be made based on clinical experience and consensus among
experts in the ﬁeld. Although optimal clinical management
becomes more challenging when evidence is less substantial, the
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13conscientious, patient-focused, and well-intended clinicians make
nearly every day. This is especially true when making a decision
about whether or not to implant an implantable cardioverter-
deﬁbrillator (ICD).
The ACC, the AHA, and the HRS ﬁrst published
guidelines for the implantation of cardiac pacemakers and
antiarrhythmia devices in 1984. Based on new data, these
guidelines were updated in 1991, 1998, 2002, 2008, and last
in 2012 (2). Although these guidelines serve as general rules,
there are multiple scenarios that have not been speciﬁcally
assessed in these guidelines. To help clinicians, the ACC
and HRS have developed appropriate use criteria (AUC) to
adjudicate the appropriateness of ICD implantation in these
not uncommon scenarios (3). The rigorous methodology of
the AUC process incorporates evidence-based medicine
gleaned from our clinical practice guidelines and randomized
controlled trials, along with practical experience from
a carefully constructed panel consisting of electrophysiolo-
gists, heart failure specialists, and general cardiologists (4).
Payers have a similar responsibility to serve the best
interests of their beneﬁciaries. However, whereas physicians
have a primary responsibility to serve the best interests of
individual patients, payers have the responsibility to assure
viability of the entire payment/reimbursement system.
Toward this end, Medicare has developed a series of
National Coverage Determinations (NCDs) to adjudicate
what medical therapies are appropriate for reimbursement.
The guiding principle underlying these determinations is the
assessment of whether an item or service is “reasonable and
necessary” for the treatment of the Medicare beneﬁciary (5).
The current NCD for primary-prevention ICD implan-
tation (6) is based on seminal trials, including, most impor-
tantly, MADIT (Multicenter Automatic Deﬁbrillator
Implantation Trial) (7), MADIT II (8), MUSTT (Multi-
center Unsustained Tachycardia Trial) (9), and SCD-HeFT
(Sudden Cardiac Death in Heart Failure Trial) (10). For
pragmatic reasons, the entry criteria for randomized
controlled trials are often restrictive, and these are used almost
verbatim by the NCD. Consequently the NCD, last revised
in 2005, does not address many of the scenarios for primary-
prevention ICD use that were considered appropriate by the
AUC authors. This leaves physicians in the uncomfortable
position of knowing that appropriate clinical recommenda-
tions may fall outside the scope of the NCD. For patients,
physicians, and insurers, these distinctions are critically
important because patient-centered care may warrant
implantation of a device appropriate for the individual
patient’s situation that does not ﬁt precisely into a covered
NCD. Importantly, this may place practitioners and hospitals
at risk for denial of payment or investigation for possible
abuse or fraud even when the decision was clinically justiﬁed.
An example might be a patient with long-standing left
ventricular dysfunction who develops complete heart block
after revascularization surgery. Implanting a pacemaker
during this hospitalization and subsequently upgrading the
device to an ICD 3 months later if the left ventricularfunction does not improve would
increase both risks and costs. The
current NCD, however, precludes
ICD implantation during this
waiting period. Another example
would be an individual resusci-
tated from a cardiac arrest who has
a small troponin elevation without
frank myocardial infarction. If the
troponin elevation is improperly
coded as a myocardial infarction,
then ICD implantation would not
be allowed.
Because the denial of reim-
bursement and potential legal
liability of fraud outlined in the
well-publicized Department of
Justice (DOJ) investigation (11) are of great concern to
physicians who prescribe and implant deﬁbrillators, we felt
this issue should be addressed. The DOJ investigation,
which initially started as a limited complaint into fraudulent
and inappropriate ICD implantation, has expanded into
an investigation of virtually all ICD implantations per-
formed early post-MI or early post-revascularization in the
Medicare program. Although many have been troubled by
the nature and scope of this investigation, we congratulate
the DOJ in recognizing that this is not a black-and-white
issue and that there are circumstances outside the scope of
the current NCD in which the decision to implant an ICD
is medically appropriate and in the best interest of the
patient. In their settlement resolution model, the DOJ
identiﬁed several “buckets” or categories of ICD implanta-
tion that although outside the scope of the current NCD will
not be subject to requests for repayment or penalties (12).
Unfortunately, these buckets are only applicable retrospec-
tively to ICDs that have already been implanted. Just
because an indication falls within the DOJ bucket list does
not indemnify the physician from future liability. The
resolution model does not replace or update the NCD and
should not be utilized to determine whether an ICD is
currently payable by Medicare.
So what should cardiologists and electrophysiologists do?
First, we believe and will strongly encourage the HRS,
AHA, and the ACC to advocate for legislation that
protects physicians who follow the clinical guidelines or the
AUC. Simply put, a physician who follows the standards of
his profession in the best interest of the patient should not
be subject to civil or criminal penalties. However, it is
important to recognize that physicians and their hospitals
have an obligation to understand the current guidelines, be
aware of the AUC scenarios, and practice within the scope
of the ICD NCD whenever possible. Conversely, we also
believe that inappropriate practice outside the guidelines
and AUC should not be tolerated. Each one of these
positions falls under the rubric of “utilizing the right
procedure at the right time for the right patient.” It is both
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14our professional responsibility and also the privilege of self-
regulation to be wise stewards of our limited healthcare
resources (13).
In the short term, if an ICD is considered medically
appropriate for the individual patient, and the implantation
falls outside of the NCD, there are several options. When
clinically appropriate, the patient may be a candidate to wear
an external deﬁbrillator vest until the requisite time period
has passed (14). Alternatively, the hospital may choose not
to charge for the device or may contact the Medicare ﬁscal
intermediary to prevent any allegation of fraudulent billing
or deception. When there is no good alternative, the patient
can be asked to sign an Advanced Beneﬁciary Notice to
acknowledge that the ICD implant may not be covered, and
he or she may be responsible for the costs of the procedure
and the device (15). We recognize these options are
imperfect.
In all cases, the line of reasoning should be documented
clearly in the medical record. Physicians who believe that
a device is indicated in a situation not covered by the
NCD must document their thought process and rationale.
All factors used in decision making, for example, ejection
fraction, functional status, and arrhythmia tracings, should
be documented in the medical record. We can also protect
ourselves and our health systems from legal action by
becoming involved with teaching coders about what
we do, what constitutes a myocardial infarction (not all
troponin elevations represent an MI), and clearly stating
in the chart when events occur, such as the diagnosis of
heart failure and the initiation of guideline-directed
medical therapy.
Finally, in the longer term, the disconnect between the
guidelines, the AUC, and the NCD must be reconciled.
Re-assessment of the NCD should be considered on
a regular basis to keep up with the latest clinical evidence.
In an ideal world, the NCD should be constructed in
a ﬂexible format enabling ease for adaptable coverage
criteria to be congruent with the evidence-based science and
appropriate clinical use. As past and current leaders of our
societies, we urge the AHA, ACC, and HRS to work
collaboratively with CMS towards this end. ICDs are life-
saving therapies. Our patients and their beneﬁciaries deserve
nothing less.
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